Snap-on Free cash flow increased by 36.5% to $347.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 26.1%, from $275.60M to $347.50M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 2.9% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $300.00M | $219.90M | $170.20M | $206.40M | $173.70M | $119.50M | $109.90M | $187.90M | $278.60M | $244.50M | $260.30M | $275.80M | $326.90M | $277.90M | $253.80M | $275.40M | $275.60M | $217.50M | $258.00M | $254.60M | $347.50M |
| QoQ Change | — | -26.7% | -22.6% | +21.3% | -15.8% | -31.2% | -8.0% | +71.0% | +48.3% | -12.2% | +6.5% | +6.0% | +18.5% | -15.0% | -8.7% | +8.5% | +0.1% | -21.1% | +18.6% | -1.3% | +36.5% |
| YoY Change | — | — | — | — | -42.1% | -45.7% | -35.4% | -9.0% | +60.4% | +104.6% | +136.9% | +46.8% | +17.3% | +13.7% | -2.5% | -0.1% | -15.7% | -21.7% | +1.7% | -7.6% | +26.1% |